These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 8917325)
21. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor therapy in the managed care era. Jacobson TA Am J Cardiol; 1996 Sep; 78(6A):32-41. PubMed ID: 8875973 [TBL] [Abstract][Full Text] [Related]
22. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. Weber C; Erl W; Weber KS; Weber PC J Am Coll Cardiol; 1997 Nov; 30(5):1212-7. PubMed ID: 9350917 [TBL] [Abstract][Full Text] [Related]
23. Advances in treatment of cholesterol abnormalities. The role of HMG-CoA reductase inhibitors. Rackley CE Postgrad Med; 1996 Nov; 100(5):61-5, 70-2. PubMed ID: 8917325 [TBL] [Abstract][Full Text] [Related]
24. Economic aspects of hypercholesterolemia treatment with HMG-CoA reductase inhibitors: a review of recent developments. MacNeil P Can J Cardiol; 1998 Apr; 14 Suppl A():14A-16A. PubMed ID: 9594928 [TBL] [Abstract][Full Text] [Related]
25. [HMG-CoA reductase inhibitors: anti-atherosclerotic effects other than lipid-lowering]. Fujita R; Matsushima T Nihon Rinsho; 1999 Dec; 57(12):2821-5. PubMed ID: 10638219 [TBL] [Abstract][Full Text] [Related]
26. Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust. Davidson MH Drugs; 2001; 61(2):197-206. PubMed ID: 11270938 [TBL] [Abstract][Full Text] [Related]
27. Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease. Rackley CE Clin Cardiol; 1996 Sep; 19(9):683-9. PubMed ID: 8874986 [TBL] [Abstract][Full Text] [Related]
28. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy. Rosenson RS Am J Cardiovasc Drugs; 2001; 1(6):411-20. PubMed ID: 14728000 [TBL] [Abstract][Full Text] [Related]
29. Comparative tolerability of the HMG-CoA reductase inhibitors. Farmer JA; Torre-Amione G Drug Saf; 2000 Sep; 23(3):197-213. PubMed ID: 11005703 [TBL] [Abstract][Full Text] [Related]
31. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. Cziraky MJ; Watson KE; Talbert RL J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279 [TBL] [Abstract][Full Text] [Related]
32. Expected versus observed survival in 3 large population studies with HMG-CoA reductase inhibitors. Naslafkih A; Sestier F J Insur Med; 2000; 32(3):155-62. PubMed ID: 15912915 [TBL] [Abstract][Full Text] [Related]
36. A review of clinical trials comparing HMG-CoA reductase inhibitors. Illingworth DR; Tobert JA Clin Ther; 1994; 16(3):366-85; discussion 365. PubMed ID: 7923304 [TBL] [Abstract][Full Text] [Related]
37. Rosuvastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia. Cheng-Lai A Heart Dis; 2003; 5(1):72-8. PubMed ID: 12549990 [TBL] [Abstract][Full Text] [Related]
38. HMG CoA reductase inhibitors. Feussner G Curr Opin Lipidol; 1994 Feb; 5(1):59-68. PubMed ID: 15559032 [TBL] [Abstract][Full Text] [Related]